logo

Alnylam Pharmaceuticals Inc. (ALNY)



Trade ALNY now with
  Date
  Headline
1/5/2023 4:03:14 PM Alnylam Pharma Appoints Carolyn Bertozzi To Its Board Of Directors
12/21/2022 8:04:16 AM Alnylam Pharma Submits CTA Application For ALN-KHK, Investigational RNAi Therapeutic For Treatment Of Type 2 Diabetes
10/27/2022 8:07:57 AM Alnylam Pharma Q3 Loss Per Share $3.32; Non-GAAP Loss Per Share $1.58
10/6/2022 8:46:32 PM Alnylam Announces FDA Approval Of SNDA For OXLUMO In Advanced Primary Hyperoxaluria Type 1
9/20/2022 7:03:09 AM Alnylam Receives Approval In Europe For AMVUTTRA For HATTR Amyloidosis In Adults With Stage 1 Or Stage 2 Polyneuropathy
9/15/2022 7:05:35 AM Alnylam And Regeneron Report Promising Data From Phase 1 Study Of ALN-HSD In NASH Patients And Healthy Volunteers
9/13/2022 6:13:50 AM Alnylam Pharma Prices Offering Of $900 Mln Of 1.00% Convertible Senior Notes Due 2027
9/12/2022 6:49:16 AM Alnylam Pharma Begins Private Offering Of $900 Mln Of Convertible Senior Notes Due 2027
9/8/2022 2:34:03 AM Alnylam Presents Positive Results From Phase 3 Study Of Patisiran In ATTR Amyloidosis With Cardiomyopathy